MARATTO

article · Benha Journal of Applied Sciences

Evaluation of Serum Human B-Defensins in Psoriasis Vulgaris Patients

2024Open accessBenha University

Abstract

Background: The overproduction of keratinocytes is a hallmark of the inflammatory skin condition known as psoriasis. The etiology of psoriasis is complex and includes both hereditary and environmental variables, including cigarette smoking, drug use, emotional and mental stress, trauma, and infections. Mucosal membranes are protected against microbes by a class of antimicrobial peptides called human beta-defensins (hBDs, −1, 2, 3). In addition to their antibacterial properties, they have other functions, such as cell activation, proliferation, migration, differentiation, angiogenesis, wound healing, and modulation of cytokine/chemokine production. The purpose of this article is to examine the relationship between the severity of psoriatic illness and the levels of human β-defensins in the serum. In conclusion, psoriasis may be influenced by serum levels of beta-defensin-2 and beta-defensin-3. Its potential as a biomarker of disease severity is shown by the association between human beta-defensin-2 and beta-defensin-3 levels and the severity of psoriasis.Background: The overproduction of keratinocytes is a hallmark of the inflammatory skin condition known as psoriasis.

Research topics

  • Antimicrobial Peptides and Activities
  • Biochemical and Structural Characterization
  • vaccines and immunoinformatics approaches

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/bjas.2024.321082.1503

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.